SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Point-of-care testing in Paediatric settings in the UK and Ireland: a cross-sectional study.

Pandey, M; Lyttle, MD; Cathie, K; Munro, A; Waterfield, T; Roland, D; GAPRUKI, PERUKI (2022) Point-of-care testing in Paediatric settings in the UK and Ireland: a cross-sectional study. BMC Emerg Med, 22 (1). p. 6. ISSN 1471-227X https://doi.org/10.1186/s12873-021-00556-7
SGUL Authors: Jarman, Heather

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (588kB) | Preview
[img]
Preview
PDF (Additional file 1) Published Version
Available under License Creative Commons Attribution.

Download (69kB) | Preview
[img] Archive (ZIP) (Additional file 2) Published Version
Available under License Creative Commons Attribution.

Download (43kB)

Abstract

BACKGROUND: Point-of-care testing (POCT) is diagnostic testing performed at or near to the site of the patient. Understanding the current capacity, and scope, of POCT in this setting is essential in order to respond to new research evidence which may lead to wide implementation. METHODS: A cross-sectional online survey study of POCT use was conducted between 6th January and 2nd February 2020 on behalf of two United Kingdom (UK) and Ireland-based paediatric research networks (Paediatric Emergency Research UK and Ireland, and General and Adolescent Paediatric Research UK and Ireland). RESULTS: In total 91/109 (83.5%) sites responded, with some respondents providing details for multiple units on their site based on network membership (139 units in total). The most commonly performed POCT were blood sugar (137/139; 98.6%), urinalysis (134/139; 96.4%) and blood gas analysis (132/139; 95%). The use of POCT for Influenza/Respiratory Syncytial Virus (RSV) (45/139; 32.4%, 41/139; 29.5%), C-Reactive Protein (CRP) (13/139; 9.4%), Procalcitonin (PCT) (2/139; 1.4%) and Group A Streptococcus (5/139; 3.6%) and was relatively low. Obstacles to the introduction of new POCT included resources and infrastructure to support test performance and quality assurance. CONCLUSION: This survey demonstrates significant consensus in POCT practice in the UK and Ireland but highlights specific inequity in newer biomarkers, some which do not have support from national guidance. A clear strategy to overcome the key obstacles of funding, evidence base, and standardising variation will be essential if there is a drive toward increasing implementation of POCT.

Item Type: Article
Additional Information: © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Keywords: Data collection, Health services research, Molecular biology, Technology, Adolescent, Child, Cross-Sectional Studies, Humans, Ireland, Point-of-Care Systems, Point-of-Care Testing, Procalcitonin, United Kingdom, GAPRUKI, PERUKI, Humans, Cross-Sectional Studies, Adolescent, Child, Point-of-Care Systems, Ireland, Point-of-Care Testing, United Kingdom, Procalcitonin, Technology, Molecular biology, Health services research, Data collection, 1103 Clinical Sciences, Emergency & Critical Care Medicine
SGUL Research Institute / Research Centre: Academic Structure > Population Health Research Institute (INPH)
Journal or Publication Title: BMC Emerg Med
ISSN: 1471-227X
Language: eng
Dates:
DateEvent
11 January 2022Published
10 November 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
PubMed ID: 35016622
Web of Science ID: WOS:000741371000002
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114940
Publisher's version: https://doi.org/10.1186/s12873-021-00556-7

Actions (login required)

Edit Item Edit Item